Oppenheimer Maintains Outperform Rating on Immunovant (IMVT) Following Q2 2026 Earnings

Core Insights - Immunovant, Inc. (NASDAQ:IMVT) is identified as a strong candidate for short squeeze opportunities following its fiscal Q2 2026 financial results, with Oppenheimer maintaining an Outperform rating and a price target of $54 [1] - The company reported an earnings per share of -$0.73, which was below the consensus estimate of -$0.71, but it holds a robust capital position with $4.4 billion in cash and no debt [1] - Immunovant is advancing its drug candidates, including IMVT-1402 for cutaneous lupus and rheumatoid arthritis, and batoclimab for Graves' disease and thyroid eye disease, with expectations for significant upside as they approach commercialization [2][3] Company Overview - Immunovant, Inc. is a clinical-stage immunology company focused on developing therapies for autoimmune diseases, particularly through anti-FcRn antibodies aimed at reducing harmful IgG autoantibodies [4]